Matrix Metalloproteinase-2 Polymorphisms in Chronic Heart Failure: Relationship with Susceptibility and Long-Term

Ana Rubia C Beber1, Evelise R Polina1, Andréia Biolo2

  • 1Laboratory of Human Molecular Genetics, Universidade Luterana do Brasil, Canoas, RS, Brazil.

Plos One
|August 24, 2016
PubMed

Insights

Matrix metalloproteinase-2 (MMP-2) gene polymorphisms may influence heart failure (HF) prognosis. Certain MMP-2 genotypes showed a trend towards reduced HF mortality in Caucasian-Brazilians, but this requires larger study confirmation.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Molecular Biology

Background:

  • Circulating matrix metalloproteinase-2 (MMP-2) levels are established predictors of mortality and hospital admission in heart failure (HF).
  • The specific impact of MMP-2 gene polymorphisms on HF susceptibility and patient outcomes remains largely uncharacterized.

Purpose of the Study:

  • To investigate the association between MMP-2 gene polymorphisms and the prognosis of heart failure patients.
  • To analyze the role of specific MMP-2 polymorphisms and their haplotypes in HF-related mortality.

Main Methods:

  • Genotyping of 308 HF outpatients and 333 healthy controls (Caucasian- and African-Brazilians) for three MMP-2 gene polymorphisms: -1575G>A, -1059G>A, and -790G>T.
  • Analysis of polymorphisms individually and as haplotypes, with adjustments for clinical covariates.
  • Longitudinal follow-up for a median of 5.3 years to assess HF-related death.

Main Results:

  • No significant differences in allele frequencies were observed between HF patients and controls across ethnic groups.
  • In Caucasian-Brazilians, the TT genotype of the -790G>T polymorphism was initially linked to decreased HF-related death risk, but this association lost significance after covariate adjustment.
  • Haplotype analysis indicated a potential association between the -1575G/-1059G/-790T haplotype and lower HF-related death rates, which also did not persist after adjusting for clinical factors.

Conclusions:

  • While this study suggests a potential link between MMP-2 gene polymorphisms, particularly -790G>T, and HF prognosis, the findings were not robust after adjusting for clinical covariates.
  • The observed associations require validation in larger, independent cohorts to confirm the role of MMP-2 polymorphisms in heart failure outcomes.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
688
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
716